COMP <GO>
ATRC vs MRK // EV/EBITDA & P/E VALUATION
AtriCure Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ATRC 5
— MRK 6
■ METRIC PARITY
LAST: $61.25 (-1.97%) • MKT CAP: $3.18B
valuation
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ATRC VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ATRC | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.00% | 74.80% | +0.20 | ATRC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -1.90% | 20.70% | -22.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.52% | 3.42% | -1.90 | MRK | /fcf-yield <GO> |
| Operating Margin | -1.80% | 34.30% | -36.10 | MRK | /operating-margins <GO> |
| Net Profit Margin | -2.10% | 28.10% | -30.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 14.90% | 1.30% | +13.60 | ATRC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.08 | 5.19 | +6.89 | ATRC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ATRC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.0 | 51.7 | +14.30 | ATRC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.18B | $361.02B | -$357.84B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ATRC REV | MRK REV | ATRC GROSS % | MRK GROSS % | ATRC FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $534.5M | $65.01B | 75.0% | 74.8% | $48.3M | $12.36B |
| FY 2024 | $465.3M | $64.17B | 74.7% | 76.3% | $745.0K | $18.10B |
| FY 2023 | $399.2M | $60.12B | — | — | $4.5M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ATRC // BETA —
MRK // BETA 0.92